A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
This is a Phase II/III, international multiple center study to evaluate the efficacy, safety, and PK of Linperlisib plus CHOP and CHOP in adult patients with Newly Diagnosed Peripheral T Cell Lymphoma.
Peripheral T Cell Lymphoma
DRUG: Linperlisib
Overall response rate, Study treatment will continue until unacceptable toxicity or documented disease progression, or for 2 years, whichever is earlier.|progression-free survival, Study treatment will continue until unacceptable toxicity or documented disease progression, or for 2 years, whichever is earlier.
This is a Phase II/III, international multiple center study to evaluate the efficacy, safety, and PK of Linperlisib plus CHOP and CHOP in adult patients with Newly Diagnosed Peripheral T Cell Lymphoma.